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Abstract The brain tissue obtained from ninety-ﬁve
cognitively unimpaired subjects, with ages ranging from
22 to 50 years upon death, were immunohistochemically
assessed for neurodegenerative changes, i.e., hyperphos-
phorylated tau (HPs) and b-amyloid (Ab) pathology in
predilection neuroanatomical areas. HPs pathology was
observed in the transentorhinal cortex and/or the locus
coeruleus (LC) in 33% of the subjects, without any
obvious risk factors known to alter the microtubule-asso-
ciated protein. HPs pathology was noted in the LC in 25
out of 83 subjects (30%), lacking concomitant cortical Ab
or transentorhinal HPs pathology. This observation was
present even when assessing only one routine section of
7 lm thickness. The recent suggestion of prion-like
propagation of neurodegeneration and the ﬁnding of neu-
rodegeneration being quite common in middle-aged
persons is alarming. It is noteworthy, however, that a
substantial number of neurologically unimpaired subjects
even at a very old age display only sparse to modest extent
of neurodegenerative pathology. Thus, only a subset of
subjects with neurodegenerative changes early in life seem
to progress to a symptomatic disease with ageing. This
observation brings forth the notion that other, yet unknown
modifying factors inﬂuence the progression of degenera-
tion that leads to a symptomatic disorder. The known
association between alterations in the LC and mood dis-
orders, and the ﬁnding of the LC being frequently affected
with HPs pathology suggest that clinicopathological
studies on young subjects both with or without mood
disorders are warranted.
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Introduction
Hyperphosphorylation of microtubule-associated protein
tau is observed in primary and secondary tauopathies [22]
as well as in aged, unimpaired individuals [26]. Braak and
Braak [5] reported that HPs is observed in Alzheimer’s
disease (AD), a secondary tauopathy, in a hierarchical way
where the ﬁrst two stages (Braak stage I and II) are char-
acterised by alteration seen in the transentorhinal cortex.
Subjects with pathology in the ﬁrst two stages are cogni-
tively unimpaired, and do not display clinical symptoms of
dementia [4, 20]. Brainstem nuclei such as the locus coe-
ruleus (LC) were reported to be involved with HPs
pathology later in the progression, starting from stage II
upward. Thus, HPs is observed in the LC in some unim-
paired aged individuals (Braak stages II–III), in subjects
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AD (Braak stages IV–VI) [8, 15].
Since the launch of the Braak-AD staging strategy, the
assessment of AD-related pathology is mostly carried out
on sections including, hippocampus and cortex [2].
Recently, however, Braak et al. reported that HPs pathol-
ogy was seen prior to entorhinal cortex in as many as 22
subjects out of 26 while assessing individuals who died
under 29 years of age (age range at death from 4 to
29 years) [7]. Furthermore, other studies have reported that
regions such as dorsal Raphe nucleus or occipital visual
association cortex (area 18/19) are in some cases affected
prior to the transentorhinal cortex [14, 23, 25].
The aim of the present study was to assess the
prevalence of HPs pathology in cognitively unimpaired
middle-aged subjects. Furthermore, the objective was to
investigate whether the LC was involved prior to the
entorhinal cortex. The assessment was carried out applying
routine sampling strategy and routine immunohistochemi-
cal (IHC) techniques.
Materials and methods
Case selection
A total of 1,505 subjects underwent a clinical autopsy,
including a neuropathological examination during the
years 1996–2008 at the Kuopio University Hospital,
Finland. Ninety-ﬁve subjects fulﬁlled the selection criteria
delineated for this study. First, the subjects should not
have displayed cognitive impairment while alive, secondly
the subjects’ age at death should not exceed 50 years, and
ﬁnally, all subjects with infectious disease in the brain or
having primary or secondary brain tumours were exclu-
ded. Demographics of the material are summarised in
Table 1.
Apolipoprotein E (APOE) genotypes were determined in
a subset of cases as previously described [31].
Neuropathological assessment
According to the standard dissection protocol used in
Kuopio University Hospital, the brains were weighed and
then immersed for at least 1 week in 10% buffered for-
malin solution and thereafter, cut into 1 cm coronal slices.
Macroscopically detectable lesions were noted. Brain
specimens were taken from 16 routinely sampled brain
regions: 1, frontal (Brodmann 9); 2, temporal (Brodmann
22); 3, gyrus cinguli; 4, parietal (Brodmann 39); 5, pre- and
postcentral gyrus; 6, occipital cortices; 7, anterior hippo-
campal formation; 8, posterior hippocampal formation; 9,
striatum; 10, basal forebrain including the amygdaloid
complex; 11, thalamus; 12, midbrain including substantia
nigra; 13, pons including LC; 14, medulla; 15, vermis and
16, cerebellar cortex. All sections were stained with
hematoxylin-eosin (HE). Cerebrovascular lesions seen in
the HE stained sections were classiﬁed as previously
described to acute, subacute, chronic or mixed (Table 2)
[1].
Immunohistochemistry
Seven micrometer thick sections were cut from formalin
ﬁxed, parafﬁn embedded tissue. The sections were depar-
afﬁnised, rehydrated in graded alcohol series. Details
regarding staining and the speciﬁc antibody applied are
summarised in Table 3. For detection, the power vision
poly HPR-IHC detection kit was used with Romulin-3-
amino-9-ethylcarbazol (AEC) chromogen. It was deter-
mined whether b Amyloid (Ab) immunoreactivity (IR) was
present or absent in the cortical sections (frontal, temporal
and parietal cortices). Braak HPs stage was given as
described previously by assessing distribution of HPs in
hippocampal sections (Table 2). In the section taken at the
level of pons, including LC, HPs-IR pretangles, neurites
and tangles were searched for under light microscopy at
940 magniﬁcation and noted as being present or absent.
Digital images were taken using an Olympus BX46
microscope equipped with an Olympus BX46 microscope
Table 1 Description of the 95 included cases
Age groups
Age at death (years)
n Gender Primary cause of death
M F Cerebral
infarct
Circulatory
failure
Neoplasia,
not brain
Infection Alcohol intoxication
and hepatic failure
Not available
20–29 6 2 4 3 1 1 1 0 0
30–39 14 8 6 9 0 2 3 0 0
40–49 63 38 25 28 17 5 7 5 1
50–59 12 7 5 6 3 2 0 0 1
All 95 55 40 46 21 10 11 5 2
n number of cases, M male, F female
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123digital camera system (Olympus Optical Co., Ltd., Tokyo,
Japan).
Results
The gender distribution of the included cases was quite
even (40 females, 55 males) (Table 1). The most common
primary cause of death was cerebral infarct (48%) and the
most common type of infarct was acute (Table 2). Seven
out of 95 subjects (7%) displayed Ab aggregates in the
cortical sections whereas 31 out of 95 subjects (33%)
displayed HPs pathology in some of the assessed regions.
In six out of 95 subjects (6%) lacking HPs,A b pathology
was seen in the cortex. Furthermore, in 30 subjects (32%)
lacking Ab,H P s pathology was seen in the entorhinal
cortex or LC. In 28 out of 95 subjects (29%), HPs-IR
lesions were seen in the LC and HPs-IR increased with age
(Tables 2, 4). All three types of lesions, i.e. pretangles,
neurites, tangles, were seen in 8 subjects (Table 4; Fig. 1).
In six subjects only pretangles were observed, in two others
only neurites, and in two other subjects, only tangles were
observed. In 3 of these 28 subjects with HPs in the LC,
HPs pathology was also observed in the entorhinal cortex
to a limited extent. Concomitant cortical Ab-IR and HPs-
IR were observed in one of these 28 subjects.
In 15 subjects (48%) with HPs pathology, a concomitant
cerebral vascular lesion was noted (Table 4); an incidence
somewhat lower when compared with the 59% that was
observed in the 64 subjects lacking HPs pathology. In 3 of
the 31 subjects with HPs pathology, the cerebrovascular
lesions were extra-axial (aneuryms), in ﬁve an acute/sub-
acute ischemic, in one acute/subacute hemorrhagic and in
the remaining six subjects, chronic or mixed infarcts were
observed. In two out of 7 subjects with Ab, concomitant
cerebral vascular lesions were observed (acute hemor-
rhagic and acute ischemic infarct) and in one case with
both Ab and HPs, an acute hemorrhagic infarct was
detected. There was no association between the type of
cerebrovascular lesions and observation of HPs pathology.
Discussion
As indicated above, 31 out of 95 (33%) unimpaired middle-
aged subjects, ranging from 22 to 50 years of age at death,
manifested HPs pathology in one or both of the assessed
regions, i.e. the transentorhinal cortex and the LC, during
assessments of routine diagnostic sections. Moreover, in 25
subjects out of 89 (28%) lacking HPs pathology in the
transentorhinal cortex, HPs pathology was seen solely in
the LC. Thus, our results are, in principle, in agreement
with Braak et al. [7] who recently reported the LC, fre-
quently being affected with HPs pathology even in very
young subjects. They reported that in as many as 22 out of
26 (85%) young subjects lacking HPs pathology in the
transentorhinal cortex, some HPs pathology was seen in the
LC. This percentage of 85%, in subjects ranging from 4 to
Table 2 Neuropathological observations in the 95 included cases
Age groups
Age at death
(years)
n Brain weight
grams
(mean ± SE)
Brain infarct (n) Hyperphosphorylated
s Braak stage (n)
b-amyloid
in the
cortex (n)
Hyperphosphorylated
s Locus coruleus (n)
Acute/
subacute
Chronic Acute/
chronic
All
(%)
0 1 2 Yes No Yes %
20–29 6 1,405 ± 79 2 0 0 2 (33) 6 0 0 1 5 0 0
30–39 14 1,550 ± 46 8 0 2 10 (71) 14 0 0 0 14 2 14
40–49 63 1,482 ± 19 26 4 4 34 (54) 57 5 1 6 57 21 33
50–59 12 1,438 ± 33 4 1 2 7 (58) 12 0 0 0 12 5 42
All 95 1,482 ± 19 40 5 8 53 (56) 89 5 1 7 88 28 29
n number of cases
Table 3 Immunohistochemistry
Antibody Code and source Clone Pretreatment Dilution Chromogen
Hyperphosphorylated s Thermoscientiﬁc MN 1020 AT8 None 1:500 Romulin AEC
Ab Dako, M0872 6F/3D 80% formic acid, 6 h 1:100 Vector Red
Ab40 BioSource, 44-348 Polyclonal 80% formic acid, 6 h 1:1,000 Vector Red
Ab42 BioSource, 44-344 Polyclonal 80% formic acid, 6 h 1:1,000 Vector Red
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12329 years of age at death, was signiﬁcantly higher when
compared to our results of 28%.
It is noteworthy that in our study the subjects were older
in comparison with subjects studied by Braak and Del
Tredici. Thus, one would have expected that the ageing-
related HPs pathology would have been observed even
more frequently in our material, given that the age at death
ranged from 22 to 50 years in our study. We noted in our
material that indeed the incidence of HPs pathology in the
LC increases with age, being 14% in the youngest and 42%
in the oldest group. There are two signiﬁcant differences
when comparing our study with the study reported by
Braak and Del Tredici. The studies differ based on: (1) the
methodology used while assessing HPs pathology and (2)
the sampling strategy of subjects.
Speciﬁcally, Braak and Del Tredici used 100 lm thick
sections in comparison with our 7 lm thick sections.
Consequently, cases displaying only occasional or few
HPs-IR neurites might have been missed, due to us
assessing sections that were 14 times thinner. Braak and
Del Tredici reported that in 12 out of 26 cases, only HPs-IR
neurites were observed in the LC (minimal pathology)
whereas in 10 out of these 26 subjects, in addition to HPs-
IR neurites, IR nerve cells were also noted (moderate
Table 4 Details regarding pathology in the 31 subjects with hyperphosphorylated s in entorhinal cortex and/or locus coeruleus
Case Age at
death
Gender APOE
e 9/e 9
Cause of
death
Cerebral infarct age of
lesion
#
b-amyloid in the
cortex
Hyperphosphorylated s
Braak
stage
Locus coeruleus
Pretangles Neurites Tangles
1 38 M na 1 Acute – – ?? –
2 39 F na 3 Acute/chronic – – ? ––
3 41 M 3/3 2 – – – – – ?
4 41 F na 1 Acute (aneurysm) – – – ? –
5 42 F na 4 – – I – – –
6 42 M na 2 Subacute – – ?? –
7 42 F 2/3 4 Acute – – ? ––
84 3 F n a 2 – – – ? – ?
9 44 M na 1 Acute(aneurysm) – I – – –
10 44 M 3/3 2 – – – ? ––
11 44 M na 2 – – – ?? ?
12 44 F na 3 – – – – ??
13 44 M na na – – I – ? –
14 44 M na 2 Acute – – – – ?
15 45 F 3/3 1 Acute (aneurysm) – – ? ––
16 45 F na 1 Subacute – – ?? ?
17 45 M na 1 Acute (hemorrhagic) Yes II ?? ?
18 46 F na 1 Chronic – I – – –
19 46 M na 4 – – – ?? ?
20 46 M 3/3 2 – – – ? ––
21 47 F na 3 – – – ?? ?
22 47 M 3/3 2 Acute/chronic – I – ??
23 49 M na 3 – – – ? ––
24 49 F 3/3 2 Chronic – – – ??
25 49 M 3/3 1 Acute/chronic – – ?? ?
26 49 M na 2 – – – – ??
27 50 M na 2 – – – ?? ?
28 50 M 3/3 2 – – – ? – ?
29 50 M 3/3 na – – – – ??
30 50 M 3/3 1 – – – ?? ?
31 50 F na 2 Acute/chronic – – – ??
F female, M male, APOE Apolipoprotein E allele, na not available, 1 cerebral infarct, 2 circulatory failure, 3 neoplasia, 4 infection
# Type of cerebral infarct, ischemic if not stated otherwise
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123amount of pathology). Thus, the ﬁnding of 10 subjects out
of 26 (38%) with IR neurites and nerve cells when
assessing 100 lm thick sections is more in line with our
results of 28%, given that we assessed sections that were 14
times thinner. While studying subjects with AD-related
pathology, Busch et al. [8] reported that there is a signiﬁ-
cant difference with regard to distribution of HPs
pathology in the LC. While carrying out a topographical
analysis, the dorsal and medial portions of the LC were
reported to be more affected when compared with the
ventral and lateral portions, emphasising the importance of
neuroanatomical sampling strategy [8]. This variation in
topographical distribution of pathology should not have
contributed to the observed differences as the sampling
strategy in our study and that of Braak and Del Tredici is
comparable, i.e. the tissue block assessed was obtained at
the level of pontine tegmentum. Thus, the primary differ-
ence in the presence of HPs pathology in the LC is
probably due to the thickness of the sections assessed, i.e. 7
versus 100 lm.
The selection strategy of subjects to be studied also
differed. The cause of death among subjects studied by
Braak and Del Tredici was quite various, including brain
tumours and transplantation of organs; all diseases asso-
ciated with heavy pharmaceutical treatment. Thus, in some
cases hyperphosphorylation of the microtubule-associated
s protein might be due to the used pharmacological ther-
apy. Agents such as cell cycle inhibitors, mitochondrial
complex I inhibitors, anti microtubule agents as well as
glucocorticoids have been reported to induce hyper-
phosphorylation of s in in vivo and in vitro studies [10, 16–
18, 30]. In addition, some of the subjects had suffered from
head injury. An association between acute head injury and
accumulation of HPs has been reported to be seen in both
experimental animal studies as well as in human studies
[12, 19, 32]. Our selection strategy was more stringent.
Speciﬁcally, we only included subjects who died acutely
without prolonged disease or heavy pharmaceutical treat-
ment. Thus most of our subjects, 67 out of 95, died due to
an acute vascular event, i.e. cerebral or cardiac insults.
Cardiovascular alterations in middle age have been sug-
gested as being a risk factor regarding cognitive decline
and dementia in later life and cardiovascular disease and
AD share many common risk factors [21, 29]. However, it
is noteworthy that cerebrovascular lesions were seen just as
frequently, both in subjects with and also without HPs
pathology. Thus, 33% of our subjects, with age ranging
from 22 to 50 years at death, displayed HPs pathology in
the transentorhinal cortex and/or locus coeruleus without
any speciﬁc known causative reason.
Interestingly, while studying drug abusers, Anthony
et al. [3] reported the LC to be affected with HPs pathology
in young subjects (age at death\30 years). It is noteworthy
that the LC was more involved than compared to the hip-
pocampus in these young subjects; a ﬁnding in line with
both our observations, and those reported by Braak and Del
Fig. 1 AT8 immunoreactive (IR) (hyperphosphorylated s) lesions in
a7 lm thick section of the locus coeruleus. a A 49-year-old
unimpaired male subject with grainy IR material, pretangle, (arrow)
in the neuronal cell body, b a 44-year-old unimpaired female with
coarse AT8-IR structure, a tangle, (arrow) in the neuronal cell body
and c a 41-year-old unimpaired female subject with thin AT8-IR
ﬁbres, dendrites, in the neuropil (arrow). Magniﬁcation 940. Scale
bar 100 lm
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123Tredici. Surprisingly, in subjects[30 years of age at death,
the HPs pathology was reported to be more severe in the
hippocampus than compared to the LC [3]. Overall, the
HPs pathology increased with age; a ﬁnding in line with
ours. Thus, based on the above it is obvious that the LC is
indeed frequently affected with HPs pathology prior to
other brain regions.
In 2004 Braak and Del Tredici stated in a commentary
that the pathological process of AD, displays a simulta-
neous involvement of the transentorhinal cortex,
magnocellular nucleus and the LC. Furthermore, in 2011
they reported that HPs pathology in the LC is frequently
seen in subjects under the age of 30 and they suggest that
this pathology might be the initiation of AD or other tau-
opathies [6, 7]. In 2011, while assessing 889 cases fulﬁlling
the Braak criteria of more than IV, Murray et al. identiﬁed
three different distributional patterns, i.e., classical (75%),
limbic predominant (14%) and hippocampal sparing
(11%). This ﬁnding suggests more than one pattern of
pathological progression of AD [24]. 33% of our unim-
paired subjects, with age ranging from 22 to 50 years at
death displayed HPs pathology in the LC and/or entorhinal
cortex. It could be interpreted from these ﬁndings that these
subjects are in a preclinical stage of a tauopathy. This
interpretation would further be in line with the report of
tauopathy spreading from one site to another in a trans-
genic mice model, indicating that tauopathy might
propagate in a prion-like way and thus, all those with HPs
pathology in the LC would in due time progress into a
tauopathy [9, 13]. The suggestion that young and middle-
aged individuals that display HPs pathology in the LC and
entorhinal cortex would progress to a symptomatic tauop-
athy is, however, controversial. A substantial number of
neurologically unimpaired subjects even at a very old age
display only sparse to modest extent of neurodegenerative
pathology and only a subset of the middle-aged subjects
with HP tau pathology in the LC and entorhinal cortex
seem to develop a dementing disorder with aging. This
observation indicates that other, yet unknown modifying
mechanisms lead to the regional progression of pathology
causing a symptomatic disorder.
It is noteworthy that most of our cases with HPs-IR
pathology in the LC did not display cortical Ab aggregates.
This ﬁnding is in line with results reported by Braak and
Del Tredici [7]. Thus, our results and the results reported
by Braak and Del Tredici are in line with the presumption
that the neuronal cytoskeletal alteration is a primary lesion
that might induce the extracellular deposits of Ab. It is also
important to note, however, that Wirths et al. [33] recently
reported that they were able to detect intraneuronal oligo-
meric assemblies of N-terminally truncated Ab peptides
starting with pyroglutamate (AbpE3), not detectable with
other commonly applied antibodies in an unimpaired
control lacking extracellular aggregates of Ab. Conse-
quently subjects, even at a very young age, should be
examined for oligomeric intracellular Ab in order to assess
which of the two pathologies, HPs or oligomeric Ab is
primarily observed.
In our study, the pathology was only seen in the tran-
sentorhinal cortex in three cases. This ﬁnding of the LC
being unaffected in these three cases might be due to the
methodological aspects discussed above. We only stained
one section, thus a minute amount of pathology could
easily have been missed. Another explanation might be
related to the hypothesis proposed by Braak and Del
Tredici [6], that of simultaneous involvement of the tran-
sentorhinal cortex, magnocellular nucleus and the LC with
HPs pathology.
Behavioural and psychological symptoms such as
depression, mood and emotional disturbances, confusion
and agitation are observed in AD patients [28]. Several
studies have suggested that pathological alteration in the
LC and substantia nigra are probably causative regarding
the depression in AD [34]. Previous assessment of the LC
in subjects with mood disorders has been centred on cell
count/loss. Assessment of HPs pathology in the LC in
subjects with the clinical diagnosis of pure mood disorders
has not been systematically carried out to our knowledge.
Association of LC pathology with depression and obser-
vation of early involvement of the LC with HPs pathology
is disturbing. First, this could suggest that a tauopathy is
initiated much earlier than previously even suspected.
Secondly, this ﬁnding might implicate that young subjects
with depression might be at risk for developing AD or
other tauopathy in later life. Rapp et al. [27] reported that
the load of pathology in subjects with AD was signiﬁcantly
higher in those who had suffered from a lifetime history of
depression, thus, suggesting an association between these
two disorders. In line with the observations above, an
association between AD and history of early onset of
depression has been reported [11]. Thus, additional post-
mortem studies assessing HPs pathology in the brain stem
of subjects of all ages with a diagnosis of a mood disorder
are urgently needed to clarify this issue.
In summary, we conclude that HPs pathology is indeed
frequently seen in the LC in unimpaired middle-aged
subjects without any obvious risk factors known to alter the
microtubule-associated protein. HPs pathology was noted
in the LC in 25 out of 83 subjects (30%) lacking con-
comitant cortical Ab or transentorhinal HPs.T h i s
observation was obtained when assessing only one section
with 7 lm thickness. The ﬁnding of frequent involvement
of LC with HPs pathology in early middle-aged subjects
raises many questions and concerns. It is not clear whether
this pathology is the primary stage of AD or other tauop-
athy or merely an insigniﬁcant alteration related to ageing.
102 Acta Neuropathol (2012) 123:97–104
123The suggestion of prion-like propagation of neurodegen-
eration would be in line with the former interpretation [13]
whereas the observation of sparse extent of pathology in
most aged subjects supports the latter. In most cases, HPs
was observed without concomitant Ab pathology. Recent
observations have shown the presence of oligomeric Ab in
aged cases without Ab aggregates. Thus, assessment of
oligomeric Ab in individuals with sparse HPs pathology
should urgently be carried out. The association between the
LC and mood disorders raises the question of whether
some subjects with a mood disorder are at risk of devel-
oping a tauopathy. Clinicopathological studies on young
subjects and particularly those with mood disorders are
thus urgently needed.
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